PD-L1在非小细胞肺癌中表达的检测方法

Detection methods of PD-L1 expression in non-small cell lung cancer

免疫检查点抑制剂(ICI)通过阻断程序性死亡受体-1(PD-1)及其配体(PD-L1),已成为非小细胞肺癌(NSCLC)的新型治疗策略,为晚期NSCLC的治疗带来了新希望。肿瘤细胞PD-L1表达可预测肺癌患者对ICI反应性,PD-L1已成为预测免疫治疗效果的生物标志物。本文拟综述NSCLC中PD-L1表达的检测方法。

Immune checkpoint inhibitors have become a new treatment strategy for non-small cell lung cancer(NSCLC)by blocking programmed death receptor-1(PD-1)and its ligand PD-L1,which opens new expectation on advanced NSCLC.PD-L1 expression of tumor cells can predict the response of ICIs in lung cancer patients and serve as a biomarker for predicting the efficacy of immunotherapy.This article aims to review the detection methods of PD-L1 expression in NSCLC.